NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 4.59 against a street estimate of 4.20 — a beat of 9.3%.
with an average price target of ₹988.00.
| Holder | Stake |
|---|---|
| SBI Healthcare Opportunities Fund | 2.85% |
| Nuvama Crossover Opportunities Fund - Series III B | 2.14% |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund | 1.81% |
| Mukul Mahavir Agrawal | 1.33% |
| Nuvama Crossover Opportunities Fund - Series III | 1.11% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call SUDEEP PHARMA LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue from operations: INR 158.3 crores in Q1 FY27, up 27% YoY (from INR 124.9 | 2026-08-11 |
| Quarterly results · Q1 FY27 SUDEEP PHARMA LIMITED - Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Revenue from Operations (Q1 FY27): Rs. 15,827.05 lakhs vs Rs. | 2026-08-04 |
| Investor presentation SUDEEP PHARMA LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue from Operations Q1FY27: Rs. 158.3 Cr, up 27% YoY (Q1FY26: Rs. 124.9 Cr) | 2026-08-04 |
| Investor presentation | 2026-08-04 |
| Annual report FY2026 SUDEEP PHARMA LIMITED – ANNUAL REPORT 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: `642.3 crores (+28% YoY) • EBITDA: `221.9 crores, | 2026-07-10 |
| Q4 FY26 earnings call SUDEEP PHARMA LIMITED – Q4 & FY26 SUMMARY HEADLINE NUMBERS • Revenue from operations FY26: INR 642.3 crores (up 27.9% YoY from INR 501.9 crores in F | 2026-05-28 |
| Investor presentation · Q4 FY26 SUDEEP PHARMA LIMITED – Q4FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue from Operations: Rs. 642.3 crore, up 28% YoY (FY25: Rs. 502.0 crore) | 2026-05-21 |
| Quarterly results · Q4 FY26 SUDEEP PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue from Operations: Rs. 64,225.80 lakhs (vs Rs. 50,199.92 lakhs in | 2026-05-21 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.50 / share ex-date Jul 23, 2026 | 2026-07-23 |
| Announcement | Date |
|---|---|
| FDA approval received for new greenfield pharmaceutical manufacturing facility in Gujarat Sudeep Pharma received approval from the Gujarat Food and Drug Control Administration for its new greenfield manufacturing facility at 179 Nandesari, Gujarat. The approval allows manufacturi | 2026-10-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sudeep Pharma Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.